70 related articles for article (PubMed ID: 20526294)
1. Diabetes drug woes spell trouble for the entire drug family.
Wadman M
Nat Med; 2010 Jun; 16(6):614. PubMed ID: 20526294
[No Abstract] [Full Text] [Related]
2. A lesson in moderation: applying pharmacodynamics to clarify the relationship between thiazolidinediones and adverse vascular outcomes in type 2 diabetes.
Lehmann DF; Lohray BB
J Clin Pharmacol; 2008 Aug; 48(8):999-1002. PubMed ID: 18650500
[No Abstract] [Full Text] [Related]
3. [The PPARgamma receptor agonists and prevention of cardio-vascular complications in patients with type 2 diabetes. The results of the PROactive study].
Szymborska-Kajanek A; Strojek K
Kardiol Pol; 2006 Mar; 64(3):322-5; discussion 325-6. PubMed ID: 16583340
[No Abstract] [Full Text] [Related]
4. Revisiting the rosiglitazone story--lessons learned.
Rosen CJ
N Engl J Med; 2010 Aug; 363(9):803-6. PubMed ID: 20660395
[No Abstract] [Full Text] [Related]
5. Thiazolidinediones.
Mascitelli L; Pezzetta F
N Engl J Med; 2005 Jan; 352(2):205-7; author reply 205-7. PubMed ID: 15651125
[No Abstract] [Full Text] [Related]
6. Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis.
Rajagopalan R; Rosenson RS; Fernandes AW; Khan M; Murray FT
Clin Ther; 2004 Sep; 26(9):1400-10. PubMed ID: 15531002
[TBL] [Abstract][Full Text] [Related]
7. Outlook on diabetes drug less than rosy. Early work suggests that rosiglitazone (Avandia) may not be best for the heart.
Harv Heart Lett; 2007 Aug; 17(12):1-2. PubMed ID: 17717888
[No Abstract] [Full Text] [Related]
8. A comment on 'the risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy'.
Chang Y; Choi NK; Hahn S; Park BJ
Pharmacoepidemiol Drug Saf; 2007 Oct; 16(10):1072-3; author reply 1073-4. PubMed ID: 17907252
[No Abstract] [Full Text] [Related]
9. Thiazolidinediones and cardiovascular risk: will the evidence so far available modify treatment strategies for type 2 diabetes?
Vaccaro O; Riccardi G
Nutr Metab Cardiovasc Dis; 2008 Feb; 18(2):85-7. PubMed ID: 18280715
[No Abstract] [Full Text] [Related]
10. [Thiazolidinediones and skeletal health].
Meier C; Bodmer M; Meier CR; Kraenzlin ME
Rev Med Suisse; 2009 Jun; 5(207):1309-10, 1312-3. PubMed ID: 19626930
[TBL] [Abstract][Full Text] [Related]
11. Thiazolidinedione-induced skeletal fragility--mechanisms and implications.
Grey A
Diabetes Obes Metab; 2009 Apr; 11(4):275-84. PubMed ID: 18671797
[TBL] [Abstract][Full Text] [Related]
12. Rosiglitazone: failure of oversight or demons imagined?
Susman J
J Fam Pract; 2007 Sep; 56(9):696, 703. PubMed ID: 17764640
[No Abstract] [Full Text] [Related]
13. [The benefit of pioglitazone in patients with diabetes mellitus type 2 and cardiovascular complications].
Olsovský J
Vnitr Lek; 2005 Dec; 51(12):1412. PubMed ID: 16430111
[No Abstract] [Full Text] [Related]
14. Pioglitazone/glimepiride (Duetact) for diabetes.
Med Lett Drugs Ther; 2007 Jan; 49(1253):9-11. PubMed ID: 17261966
[No Abstract] [Full Text] [Related]
15. Rosiglitazone/glimepiride (Avandaryl) for diabetes.
Med Lett Drugs Ther; 2006 Mar; 48(1230):22-4. PubMed ID: 16538189
[No Abstract] [Full Text] [Related]
16. Lessons from the Avandia controversy: a new paradigm for the development of drugs to treat type 2 diabetes.
Misbin RI
Diabetes Care; 2007 Dec; 30(12):3141-4. PubMed ID: 18042753
[No Abstract] [Full Text] [Related]
17. The rosiglitazone meta-analysis.
McCullough PA; Lepor NE
Rev Cardiovasc Med; 2007; 8(2):123-6. PubMed ID: 17603430
[No Abstract] [Full Text] [Related]
18. [Stop selling rosiglitazone].
Johansen K
Ugeskr Laeger; 2007 Sep; 169(36):3007. PubMed ID: 17966148
[No Abstract] [Full Text] [Related]
19. Rosiglitazone + glimepiride: new drug. Another combination product to avoid.
Prescrire Int; 2007 Aug; 16(90):144. PubMed ID: 17726795
[No Abstract] [Full Text] [Related]
20. [Treatment of patients with type 2 diabetes mellitus with pioglitazone. A survey of a Cochrane review].
Madsbad S
Ugeskr Laeger; 2007 Nov; 169(47):4054-7. PubMed ID: 18078659
[No Abstract] [Full Text] [Related]
[Next] [New Search]
